SCHEMBL7344445

SCHEMBL7344445

CCOc1cccc(NC(=O)c2ccc3cc(C=NN)ccc3c2)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PLAU P00749 4/20 0.68
▸ NPC1 O15118 3/20 0.57
▸ RAB9A P51151 2/20 0.57
▸ POLB P06746 1/20 0.57
▸ CASP3 P42574 1/20 0.57
▸ SENP8 Q96LD8 1/20 0.57
▸ SENP7 Q9BQF6 1/20 0.57
▸ SENP6 Q9GZR1 1/20 0.57
▸ KMT2A Q03164 3/20 0.57
▸ SMN1; SMN2 Q16637 2/20 0.57
▸ NR1H4 Q96RI1 1/20 0.56
▸ RECQL P46063 2/20 0.55
▸ LMNA P02545 5/20 0.53
▸ MAPT P10636 3/20 0.52
▸ THRB P10828 1/20 0.51
▸ TP53 P04637 1/20 0.51
▸ MEN1 O00255 2/20 0.50
▸ F2 P00734 1/20 0.50
▸ PLG P00747 1/20 0.50
▸ PLAT P00750 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7342735 0.92 THRB (0.57) PLAUNPC1RAB9APOLBCASP3
SCHEMBL7345171 0.88 PLAU (0.69) PLAUNPC1RAB9APOLBCASP3
SCHEMBL7341946 0.87 PLAU (0.67) PLAUNPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL7344354 0.87 NR1H4 (0.59) PLAUNPC1RAB9AKMT2ANR1H4
SCHEMBL7337848 0.85 PLAU (0.67) PLAUNPC1RAB9ACASP3SENP8
SCHEMBL7336657 0.84 NR1H4 (0.54) PLAUNR1H4F2PLGPLAT
SCHEMBL7344439 0.81 PLAU (1.00) PLAUNPC1RAB9APOLBCASP3
SCHEMBL7340961 0.81 PLAU (0.70) PLAUNPC1RAB9AKMT2AMEN1
SCHEMBL7340942 0.80 PLAU (0.67) PLAUNPC1RAB9ACASP3SENP8
SCHEMBL7337325 0.80 PLAU (0.58) PLAUNPC1RAB9ACASP3SENP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6284796-B1 NAPHTHAMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-09-04 — — US claimed
US-20010049374-A1 Urokinase inhibitors STEELE ANDREW W (US) 2001-12-06 — — US disclosed
US-6284796-B1 NAPHTHAMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-09-04 — — US disclosed
US-6258822-B1 ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-07-10 — — US disclosed
EP-1000018-A2 UROKINASE INHIBITORS Abbott Laboratories (US) 2000-05-17 — — EP disclosed
WO-1999005096-A2 UROKINASE INHIBITORS ABBOTT LABORATORIES (US) 1999-02-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010049374-A1 Urokinase inhibitors SERPINE1, PLAU, SERPINB1 PLAU 2/4885NPC1 2478/4885RAB9A 2845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback